[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Charles Raison\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100648206","phase-1-psilocybin-effects-on-healthy-aging-biomarkers-and-purpose-in-life-100648206",false,"NCT07719088","Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life","An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life","LONG-LIFE","Inclusion Criteria:\n\n* English speaking and able to provide informed consent and complete study procedures\n* Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject.\n\nExclusion Criteria:\n\n* History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results.\n* Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician).\n* Unwilling or unable to discontinue medications that may interfere with study participation, as determined by the investigator.",true,"ALL","60 Years","80 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose\u002Fmeaning in life in medically stable older adults.\n\nUp to 50 participants will be enrolled aged 60-80 who will be randomized with equal allocation to one of four intervention groups: (1) receipt of one 25 mg dose of psilocybin; (2) receipt of two 25 mg doses of psilocybin separated by four weeks; (3) receipt of three 25 mg doses, with each dose separated by four weeks; or (4) wait-list comparator condition that does not receive psilocybin. Biomarkers of aging, cognitive performance, and behavioral measures will be assessed at baseline and longitudinally over a 12-month follow-up period. The primary endpoint occurs at the Week 16 visit. Participants randomized to the wait-list condition will be offered a single 25 mg dose of psilocybin following conclusion of the 12-month follow-up period.\n\nFindings from this Phase I study will inform dose selection for a Phase II study should results indicate a potential impact of psilocybin on relevant study endpoints.",[29,30,31],"Aging","Longevity","Biomarkers of Aging",[29,30,33,34,35,36,37],"Cognitive Function","Purpose","Meaning","Well-Being","Biomarkers","NOT_YET_RECRUITING","2026-08-13",{"date":41,"type":42},"2026-08-17","ACTUAL",{"date":44,"type":23},"2026-12",{"date":46,"type":23},"2028-12",{"name":48,"class":49},"Charles Raison","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":50},"100555446","investigation-to-understand-and-optimize-psilocybin-100555446","NCT06512194","Investigation to Understand and Optimize Psilocybin","An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)","OPTIMIZE","Inclusion Criteria:\n\nCurrent diagnosis of Major Depressive Disorder (MDD), with a depressive episode lasting ≥ 60 consecutive days at the time of screening, as confirmed by structured clinical interview\n\nMedically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject.\n\nExclusion Criteria:\n\nHistory or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results (e.g., bipolar disorder, psychosis, seizure disorder, or cardiovascular disease).\n\nKnown family history of a psychotic disorder (e.g., schizophrenia or schizoaffective disorder) in a first-degree relative (biological parent, full sibling, or child).\n\nCurrent active suicidal ideation with a specific plan within the prior 2 weeks, as assessed via clinical interview and validated instrument (e.g., C-SSRS).\n\nSuicide attempt within the prior 6 months, regardless of intent or lethality.\n\nCurrent diagnosis of a substance use disorder\n\nAbnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician).\n\nUnwilling or unable to discontinue prescription psychotropic medications (e.g., antidepressants, antipsychotics, anxiolytics, lithium, anticonvulsants, or mood stabilizers) for the duration of study participation, including any necessary washout period as determined by the investigator.\n\nAny condition, finding, or behavior (including suspected deception or noncompliance) that, in the opinion of the investigator, renders the participant unsuitable for the study or likely to interfere with the integrity of the data or safety of the subject.","18 Years","70 Years",{"count":62,"type":23},141,[64],"PHASE2","This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.",[67],"Depression",[69,70,71,72,73,74,75,76,77,78],"depression","psilocybin","psychedelics","transcutaneous auricular vagus nerve stimulation","depressive symptoms","well-being","adverse events","ecological momentary assessment","electronically activated recorder","dynamical complexity assessment","RECRUITING","2026-08-05",{"date":82,"type":42},"2026-08-10",{"date":84,"type":42},"2025-05-13",{"date":86,"type":23},"2029-05",{"name":48,"class":49},""]